Cardiogen (Bioregulator)

Cardiogen and the Heart

Within the heart, Cardiogen seems to stimulate the proliferation of cardiomyocytes while limiting the growth and development of fibroblasts. This unique action results in reduced scar formation and improved long-term outcomes, particularly in cases of cardiac remodeling leading to heart failure. Moreover, Cardiogen at a 20mg dosage may decrease p53 protein expression, leading to lower rates of apoptosis in cardiac cells[1].

Cardiogen and Cancer

Although Cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, its impact on tumor cells appears to be the opposite. Research conducted on rat models with M-1 sarcoma suggests that Cardiogen administration increases apoptosis levels in tumor cells. Notably, this effect varies with dosage, indicating its genuine biological effect[2]. Cardiogen’s potential to enhance apoptosis in tumor cells, especially with an enhanced and unusual vascular supply, makes it a candidate for targeted cancer treatment. Additionally, if it can enhance the effects of standard cancer treatments, as seen in heart disease treatment, it could become a potent tool in the fight against cancer.

Cardiogen and the Prostate

Research using tissue cultures has demonstrated that Cardiogen and similar peptides can alter the expression of signaling factors in prostate fibroblasts. These signaling factors play a crucial role in creating a favorable microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Studies have revealed that aging and senescent fibroblasts exhibit substantial changes in the synthesis of these markers, possibly explaining the prevalence of prostate cancer in older men and its rarity in younger individuals[3]. Remarkably, Cardiogen has the ability to normalize the levels of these signaling molecules, potentially serving as a preventive measure for prostate cancer and aiding in its control once it has developed[4].

Cardiogen in Summary

Cardiogen 20mg, though less extensively researched compared to some other bioregulators, exhibits potent effects on various body tissues, including the heart and prostate. It also holds promise in cancer treatment, particularly in cases of sarcoma. Currently, Cardiogen’s primary benefits seem to be in addressing heart conditions such as heart attack, hypertension, and chronic heart failure. What sets Cardiogen apart is its ability to complement established treatments, offering improved therapeutic outcomes.

Cardiogen is associated with minimal side effects, boasts good oral and excellent subcutaneous bioavailability in mice. It is important to note that the mouse-based dosage does not scale directly to humans. For this reason, Cardiogen is available for purchase at Peptide Sciences exclusively for educational and scientific research purposes, with no intent for human consumption. It is restricted to licensed researchers only.